Company Overview: Keryx Bio

Industry News

26 Feb

What Awaits Keryx Biopharmaceuticals (KERX) this Earnings? – Analyst Blog

Keryx Biopharmaceuticals, Inc. (KERX) is scheduled to report its fourth-quarter and full-year 2014 results on Feb 27, 2015. Keryx’s track record has been dismal in the first nine months of 2014 with the company reporting wider-than-expected losses in all of the last four quarters. The average earnings miss over...

Read more

11 Dec

Healthcare Sector Movers: Keryx Biopharmaceuticals Inc. (KERX), ACADIA Pharmaceuticals Inc. (ACAD), Smith & Nephew plc (SNN), Stryker Corporation (SYK), Agilent Technologies Inc. (A)

Keryx Biopharmaceuticals Inc. (KERX) has moved with a change from open of 1.51% at mid-day today with a volume of 725,028 shares.  Keryx Biopharmaceuticals Inc. (KERX) is currently trading at $15.51 with a weekly performance of – 2.65% and a 52 week low of 34.52%.  Keryx Biopharmaceuticals Inc. (KERX)’S...

Read more

2 Dec

Auryxia(TM) (Ferric Citrate) Phase 2 Data Published in the American Journal of Kidney Disease

Study Evaluated Auryxia in Non-Dialysis Dependent Chronic Kidney Disease (CKD) Patients Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced the publication of Auryxia phase 2 clinical trial results in non-dialysis dependent chronic kidney disease (NDD-CKD) patients...

Read more

26 Jul

Keryx Bio

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address